Moderna (MRNA): $145M Revenue, a $4.7B Cost Base — And the Norovirus Miss That Broke the Rally

Moderna, Inc. (MRNA) Q2 2026 — Q2 2026 = the three months ended 30 June 2026, reported 31 July. Revenue $145M vs $142M — but NET PRODUCT SALES FELL to $94M from $114M while other revenue (grants, collaboration, stand-ready manufacturing) rose to $51M from $28M. Operating expenses $960M. Loss from operations $(815)M. Net loss $(782)M, better by $43M. GAAP EPS $(1.97) vs $(2.13) — in line; the beat was on revenue (~$127M expected). Cash and investments $6.9B. The stock closed at $54.82, DOWN 5.35%, eight cents off the low of the day. A revenue beat closed down 5% because mRNA-1403, Moderna's norovirus vaccine, did NOT meet the criteria for early success at its Phase 3 interim. The $6.9B cash figure is also stale — $950M was paid in JULY on the Q1 litigation settlement, and year-end cash is guided to $4.7-5.2B. THE CALL: SELL (4/5, A PLATFORM PRICED AS A FRANCHISE) — base-case value ~$16.25 vs ~$54.82 today. KEY METRICS: - Revenue $145M vs $142M — but NET PRODUCT SALES fell 18% to $94M; other revenue rose 82% to $51M. US $87M / intl $58M - Cost of sales $93M (-22%): $41M inventory write-downs + $23M unutilised capacity + $11M royalties — 69% of COGS is not the cost of product. Gross margin 36% GAAP, ~80% ex those charges - R&D $651M (-7%) = 4.5x total revenue. SG&A $216M (-6%). Total opex $960M vs $1,049M. Operating loss $(815)M - The $43M y/y improvement, exactly: revenue +$3M, opex +$89M; then interest income -$14M, other -$27M, tax -$8M — 100% of it came from spending less - Cash + investments $6,910M at 30 Jun vs $591M long-term debt = ~$6.32B NET CASH. $950M PAID IN JULY on the settlement -> pro-forma ~$5.96B - 1H26: revenue $534M, net loss $(2,125)M, operating cash flow $(1,156)M, capex $99M, SBC $224M; retained earnings $7,223M -> $5,098M - 2026 GUIDANCE: revenue up to +10% on 2025's $1,944M (<=$2.14B); cost of sales ~$1.7B (incl. $0.9B litigation charge); R&D ~$2.9B; SG&A ~$1.0B; year-end cash $4.7-5.2B; ~55% of 2H revenue in Q3 - SEASONALITY — DO NOT ANNUALISE Q2: Q2'25 $142M, Q3'25 $1,016M, Q4'25 $678M, Q1'26 $389M, Q2'26 $145M. Trailing twelve months $2,228M - PIPELINE: mFLUSIVA PDUFA 5 Aug (unanimous VRBPAC) = a 5th product; mCOMBRIAX authorised in the EU; mRNA-1403 norovirus MISSED its Phase 3 interim; intismeran with Merck in 9 Phase 2/3 trials, adjuvant melanoma fully enrolled (ASCO: 49% lower risk of recurrence or death vs KEYTRUDA alone) - PATH TO PROFITABILITY: recurring cost base ~$4.7B. At a 72% gross margin Moderna needs ~$5.4B of revenue to cover $3.9B of R&D+SG&A — ~2.5x the 2026 guide, or a ~60% cut to R&D and SG&A - OUR DCF at 11.5%, mid-year timing, on $6.32B of net cash: bear $2.60 / base $15.90 / bull $30.50; weighted 25/50/25 = ~$16.25 vs $54.82. Even the BULL case is 44% below the close - REVERSE DCF: at $54.82, equity $21.75B and EV ~$15.43B (6.9x trailing revenue). That requires ~$3.65B of sustainable 2032 free cash flow — ~$14.6B of revenue at a 25% margin, 7x this year's guide — or a 5.1% cost of equity - STREET: Hold across 27 analysts (7 buy / 16 hold / 4 sell), average target $46.11, median $45.00 — already 15.9% BELOW the traded price What to watch: Bullish triggers: a clearly positive Phase 3 adjuvant melanoma read-out for intismeran (fully enrolled, data possible in 2026), or mFLUSIVA approved on 5 August and taking real share of the US flu market in its first season. Bearish confirmation: a Q3 revenue miss (55% of second-half revenue is guided into that one quarter), any equity raise or convertible, or an Analyst Day on 12 November that still contains no breakeven date. We'd look again nearer ~$25. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.